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Abstract
Introduction. Pancreas cancer is the fourth commonest cause of cancer-related mortality across the world, with incidence
equalling mortality. A recent study has suggested that both the incidence and the mortality of pancreatic cancer are falling in
the UK. We investigated whether this trend was being seen all over the world. Methods. Age-standardized mortality (world)
rates [ASR(W)] for pancreatic cancer were extracted separately for males and females from a database maintained by the
International Agency for Research on Cancer for 51 countries across the world (Europe, 33 countries; Americas, 8
countries; and Asia, 10 countries) for the period 19922002; log-linear regression analysis was performed to analyse trends
in the past decade. Results. In the period 19922002, the ASR(W) remained static across most countries for both sexes. The
highest mortality rates (for both sexes) were seen in Central Europe [range: men (812), women (4.57)] with trends
towards increasing mortality in Romania (pB0.001), along with Albania, Spain and Croatia (pB0.01). Korea in the Far
East, too, demonstrated increasing mortality trends for both sexes (men pB0.001, women pB0.01). Increasing mortality
trends were also observed among women in France (pB0.001). In Canada, there was a decline in mortality [men (7.56.4),
women (5.95); pB0.01], while for men there was a downward trend in Ireland, the UK, Switzerland, Austria, and Poland
[pB0.05]. Conclusion. The changes perhaps reflect standardization and consolidation of diagnostic tests for pancreatic
cancer in the Western world and further in-depth analysis would be required.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the
most common epithelial, exocrine pancreatic malig-
nancy, i.e. accounting for more than 80% of the
malignant neoplasms of the pancreas [1]. It remains
the fourth most common cause of cancer-related
death in the Western world [2]. The incidence of
pancreatic cancer correlates with increasing age with a
peak incidence of the disease occurring in the 6575
year age group [3]. Untreated metastatic pancreatic
cancer has a median survival of 35 months and 610
months for locally advanced disease [4]. The majority
of cases are diagnosed in the advanced stages, making
curative therapy impossible and leading to poor
prognosis and incidence equalling mortality [5]. In
the year 2000, there were 217,000 new cases of
pancreatic cancer with 213,000 deaths worldwide,
while in Europe there were 60,139 new patients with
64,801 deaths [6]. In the UK, 7,152 new cases were
seen with 7,250 deaths as a result of PDAC [7].
PDAC affects more individuals inhabiting the Wes-
tern/industrialized parts of the world; the highest
incidence has been reported among Maoris in New
Zealand, native Hawaiians and Black American po-
pulations, while people living in India and Nigeria
have the lowest reported incidence [8,9]. Being Jewish
increases the risk of developing PDAC as compared to
other religious faiths [10]. Northern and central
Europe have a higher incidence of pancreatic cancers
compared to southern Europe, while in the United
States immigrant populations (Scandinavian, eastern
European, and Japanese) living in urban areas have
higher incidence rates compared with native popula-
tions [8,11]. A recent study from England and Wales
suggests that the incidence, as well as mortality, for
pancreatic cancer perhaps fell over the period 1951
2000. This was particularly pertinent for the male
population towards the end of the last century (1996
2000). We investigated whether similar trends could
be seen across the world.
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Methods
The database maintained by the International Agency
for Research on Cancer (IARC) CANCER Mondial
Statistical Information System (http://www-dep.iarc.
fr/) was accessed and age-standardized mortality rate
(world) [ASR(W)] due to pancreatic cancer was
extracted separately for males and females for the
period 19922002 for 51 countries across the world.
Data were available from 33 countries in Europe
(Western Europe: Belgium, France, Germany, Ire-
land, Luxemburg, The Netherlands, Switzerland and
the United Kingdom; Eastern Europe: Bulgaria,
Estonia, Latvia, Lithuania, Moldova, Poland and
Romania. Northern Europe: Denmark, Finland, Ice-
land, Norway and Sweden; Southern Europe: Alba-
nia, Croatia, Greece, Italy, Macedonia, Malta,
Portugal, Slovenia and Spain; Central Europe: Aus-
tria, Czechoslovakia, Hungary and Slovakia), 10
countries in Asia (South East Asia: Hong Kong,
Philippines and Singapore; Far East: Japan and
Korea; Northern Asia: Georgia, Kyrgyzstan and
Russia; Middle East: Israel and Kuwait) and 8
countries across the Americas (North America: Ca-
nada and the USA; South America: Argentina, Chile,
Costa Rica, Mexico, Uruguay and Venezuela). Log-
linear regression analysis on ASR(W) was used to
Table I. Significant trends in the mortaility of pancreatic cancer, 19922002.
Males Females
Country coefficient 95% CI p-value coefficient 95% CI p-value
Eastern Europe Bulgaria NS 0.021 (0.006, 0.036) 0.01
Estonia NS NS
Latvia NS NS
Lithuania NS NS
Moldova NS NS
Poland 0.006 (0.012, 0.001) 0.02 NS
Romania 0.02 (0.014, 0.026) B0.001 0.023 (0.016, 0.030) B0.001
Southern Europe Albania 0.077 (0.033, 0.121) 0.003 0.104 (0.044, 0.163) 0.003
Croatia 0.033 (0.016, 0.050) 0.002 0.027 (0.004, 0.051) 0.03
Greece 0.009 (0.002, 0.020) 0.09 0.014 (0.004, 0.023) 0.01
Italy NS 0.006 (0.0003, 0.012) 0.06
Macedonia NS NS
Malta NS 0.06 (0.007, 0.114) 0.03
Portugal NS NS
Slovenia NS NS
Spain 0.011 (0.006, 0.016) 0.001 0.012 (0.003, 0.021) 0.02
Western Europe Belgium NS NS
France NS 0.014 (0.008, 0.020) B0.001
Germany NS 0.004 (0.0003, 0.008) 0.04
Ireland 0.015 (0.30, 0.001) 0.04 NS
Luxembourg NS NS
Netherlands NS NS
Switzerland 0.013 (0.025, 0.002) 0.03 NS
UK 0.008 (0.013, 0.002) 0.01 NS
Central Europe Austria 0.012 (0.020, 0.004) 0.01 NS
Czechoslovakia NS NS
Hungary NS NS
Slovakia NS NS
Northern Asia Georgia NS NS
Russia 0.043 (0.011, 0.096) 0.08 0.053 (0.019, 0.125) 0.09
Kyrgyzstan NS NS
North East Asia Japan NS 0.004 (0.001, 0.007) 0.02
Korea 0.028 (0.017, 0.039) B0.001 0.26 (0.014, 0.039) 0.001
South East Asia China NS NS
Philippines NS NS
Singapore NS NS
Thailand NS NS
North America Canada 0.013 (0.018, 0.007) 0.001 0.008 (0.012, 0.003) 0.006
USA 0.003 (0.006, 0.0002) 0.07 NS
South America Colombia NP NP
Costa Rica NP NP
Ecuador NP NP
Mexico NP NP
Uruguay NP NP
Venezuela NP NP
NSnot significant; NPnot performed; CIconfidence interval.
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analyse trends for the period 19922002. Correlation
coefficients were calculated; a positive value indicated
an increasing trend, while a negative value was
indicative of a falling trend; pB0.05 was considered
significant.
Results
The age-standardized mortality rate due to pancreatic
cancer in the period 19922002 remained static for
both males and females across most of the 51
countries of the world included in our study. The
trends are summarized in Table I.
Mortality (ASR(W)) rates were highest in Central
Europe for both sexes [range: men (812), women
(4.57)] with highly significant trends towards in-
creasing mortality in Romania [men (6.28.2), wo-
men (3.24.2); pB0.001] along with Albania [men
(24), women (0.82.2); pB0.01]. Increasing mor-
tality trends that attained significance in both sexes
were also seen in Spain and Croatia (men pB0.001,
women pB0.05; see Figures 1 and 2). In the Far East,
Korea demonstrated highly significant increasing
mortality trends for both sexes [men (4.87.8), pB
0.001; women (2.54), pB0.01), while women in
Japan showed an increasing trend that was significant
(pB0.05). In France, a trend towards increasing
mortality was observed among women (pB0.001).
An upward mortality trend in women achieving
significance was also seen in Malta, Bulgaria, Greece,
and Germany (pB0.05). A decline in mortality was
seen in both sexes only in Canada [men (7.56.4),
women (5.95); pB0.01], while for men there was a
downward trend noticeable in Ireland, Switzerland,
Austria, the UK, and Poland [pB0.05].
In the Middle East, Israel showed a dramatic drop
in mortality in both sexes from around 8 in 2001 to 0
in 2002 in men, and 6 in 2001 to 0 in 2002 in women,
but the overall changes in trends for the period 1992
2002 were insignificant for both men and women.
The data from South America were poor and hence
analysis of trends from this region could not be
performed.
Discussion
Our analysis suggests that in the Western world the
mortality due to pancreatic cancer fell in the last
decade of the second millennium. This fits well with
the data published recently for England and Wales
[12]. However, this is in stark contrast to an increase
seen in Southern Europe and North East Asia. The
reasons for the changes observed could be multiple.
The first possibility is the variation in quality of data
available in international registries, along with an
absence of incidence data, population size, and
demographics [11,13]. We have, thus, assumed the
effects in all countries to be equivalent regardless of
population size. However, the fact that we used
ASR(W), a standard comparative tool, can account
for some of the variation. Secondly, the observed
variations could reflect a consolidation of use of
diagnostic modalities and may thus reflect artificial
changes in incidence and mortality rates for pancrea-
tic cancer. For example, the use of CT-guided or
EUS-guided biopsy is now a norm in the West, but is
not well established in the Southern European coun-
tries, though there is an increasing use of cross-
sectional imaging. Thus, the initial increase seen in
the West during the 1980s (due to increasing use of
cross-sectional imaging) may be mirrored in the
Figure 1. Mortality (ASR(W)) due to pancreatic cancer in males in Southern Europe during the period 19922002, smoothed using
quadratic regression.
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Southern European countries in the 1990s. However,
without biopsy, the differential diagnosis of pancreatic
cancers such as chronic pancreatic and other peri-
ampullary tumors remains and thus there may be an
artificial increase in recording of pancreatic cancer
with the increasing diagnosis of peri-ampullary
masses.
Lastly, we have to consider whether the changes we
have observed are real. However, further in-depth
analysis is required for definitive trends to be ascer-
tained. Hence, larger datasets would be required over
longer periods (more than 20 years) along with
incidence data and demographics. These data are
currently unavailable for the majority of countries.
There are multiple risk factors identified for pan-
creatic cancer. Pancreatic cancer is known to affect
older individuals, as only 10% of patients develop
this condition below the age of 50; data from the
United States show a dramatic increase in rates of
pancreas cancer from 9.8/100,000 (age group 5054)
to 57/100,000 (age group 7074) [3]. Smoking is the
strongest environmental risk factor. A meta-analysis
of cohort and case-control studies shows a significant
correlation between cigarette smoking and pancreas
cancer, the risk increasing with the number of
cigarettes smoked [14]. The prevalence of cigarette
smoking among Korean men is regarded as the
highest in the world (65.4% in 2001) [1517], which
may account for the higher mortality due to pancrea-
tic cancer in this region. Similarly, the data for
prevalence of smoking among Central Eastern and
some Southern European countries, though sparse,
suggests that smoking is not declining, but in some
countries may be increasing across both sexes [18]. In
contrast, there are reports of decreasing trends in the
incidence of smoking-related cancers across Western
Europe [19].
We are thus unable to completely explain the rise
and fall of pancreatic cancer-related mortality in
different parts of the world, though some insights
may be gained from this preliminary study indicating
that smoking may effect the changes seen. Addition-
ally, the change in use of various diagnostic modalities
may explain the differences seen in our study. The
epidemiologies of pancreatic and related cancers
deserve a more in-depth study in the near future
when more data become available.
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